Hypertension remains the leading cause of cardiovascular morbidity and premature mortality worldwide. A central contributor to this burden is impaired baroreflex function, a key regulatory mechanism of blood pressure and autonomic balance. Conditions such as chronic kidney disease, ischemic heart disease, and heart failure disrupt baroreflex sensitivity, leading to maladaptive sympathetic overactivity and disease progression.

Our research focuses on uncovering the molecular and cellular mechanisms that govern baroreceptor function in hypertension and cardiovascular disease. We investigate the mechanosensory proteins that enable baroreceptors to detect changes in vascular stretch, and we explore how dynamic modulation of G protein–coupled receptors (GPCRs) and hormone/neuropeptide signaling fine-tunes baroreflex sensitivity. .

Beyond fundamental mechanisms, our work aims to translate these discoveries into innovative therapeutic strategies. We are developing novel pharmacological approaches targeting neurovascular dysfunction, with applications ranging from rare disorders such as erythromelalgia to broader pathologies involving pathological neovascularization, including cancer and inflammatory diseases.